ClinicalTrials.gg
CompletedNCT00234065Updated Jun 10, 2011Results posted

Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)

A Phase 4 interventional study of Cilostazol and Aspirin in Cerebral Infarction, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2011-06-10.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,800
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing cilostazol in Cerebral Infarction — 1 open to participants now, 1 under way, none of them phase 3. Cilostazol · Cerebral Infarction.

Enrollment
Largest of 10
2,800 · median 594
Started
2003
the only one that year
Phase 4
8 of 10
1 open now
Registered
3rd of 10
by date
Lead sponsor
2 of 10
Otsuka Pharmaceutical Co., Ltd.

Among the 10 studies testing cilostazol in Cerebral Infarction, this one has the largest enrollment, is the only one that started in 2003, is one of 8 in phase 4, and was the 3rd registered.

Cerebral Infarction

219 studies on the registry are indexed under Cerebral Infarction; 46 are open to participants now.

Browse Cerebral Infarction studies →

Open to participants now

1 of the 10 studies testing cilostazol in Cerebral Infarction is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About cilostazol

Cilostazol: first FDA approval 1999 (PLETAL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 27 Cerebral Infarction studies recruiting now, 19 (70%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing cilostazol in Cerebral Infarction, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the efficacy of cilostazol in preventing recurrence of cerebral infarction and the safety of long-term administration of the drug (100 mg, twice daily) in patients with cerebral infarction (excluding cardiogenic cerebral embolism) in a multi-center, double-blind, parallel-group comparison with aspirin (81 mg, once daily).

03

Conditions studied

  • Cerebral Infarction

Browse trials for

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with stable medical conditions for 182 days (26 weeks) after occurrence of cerebral infarction
  2. Patients in whom the infarct-related foci was detected by X-ray CT scan or MRI
  3. Patients aged 20 to 80 years (inclusive) at time of consent
  4. Patients with none of the following cardiac diseases that may be associated with cardiogenic cerebral embolism: mitral stenosis, prosthetic heart valve, endocarditis, myocardial infarction within 6 weeks after occurrence, ventricular aneurysm, endocardial thrombosis, mitral valve prolapse (patients less than 45 years of age in whom no other cause was identified), atrial fibrillation, sick sinus syndrome, idiopathic cardiomyopathy, and patent foramen ovale
  5. Patients without asymptomatic cerebral infarction
  6. Patients who have neither undergone nor are scheduled to undergo percutaneous transluminal angioplasty or revascularization for the treatment of cerebral infarction
  7. Patients without severe disturbances/impairments following occurrence of cerebral

Exclusion criteria

Exclusion Criteria:

  1. Patients with hemorrhage or bleeding tendency (hemophilia, capillary fragility, intracranial hemorrhage, hemorrhage in the digestive tract, hemorrhage in the urinary tract, hemoptysis, and hemorrhage in the vitreous body)
  2. Pregnant, possibly pregnant, or nursing women
  3. Patients with ischemic heart failure
  4. Patients with peptic ulcer
  5. Patients with severer blood disorders
  6. Patients with severe hepatic or renal
  7. Patients with malignant neoplasm or patients who have received any therapy for malignant neoplasm within 5 years prior to entering the study
  8. Patients with a history of to salicylic acid formulations or ingredients of cilostazol tablets
  9. Patients with aspirin asthma (asthma attacks induced by nonsteroidal antiinflammatory analgesic agents) or a history of aspirin asthma
  10. Patients who are being treated with ticlopidine hydrochloride
  11. Patients who are participating in another study for an drug
  12. Patients who are otherwise judged inappropriate for inclusion in the study by the investigators
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,800 participants (actual)

Study arms

  • Experimental
    1

    cilostazol

    Drug: Cilostazol

  • Active comparator
    2

    Aspirin

    Drug: Aspirin

Interventions

  • oral tablet, 100 mg twice a day and placebo of aspirin once a day, 1 to 5years

  • oral tablet, placebo of cilostazol twice a day and 81 mg once a day, 1 to 5 years

06

What researchers measure

Primary outcomes

  1. Numbers of Patients With First Occurence of Stroke

    The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction, or occurrence of cerebral haemorrhage or subarachnoid haemorrhage. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints.

    Time frame: From start of treatment to end of follow-up period ( follow-up periods : 29 months [Standard Deviation 16, range 1-59 months])

Secondary outcomes

  1. Number of Patients With First Recurrence of Cerebral Infarction

    Time frame: From start of treatment to end of follow-up period (mean follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])

  2. Number of Patients With First Occurrence of Ischaemic Cerebrovascular Disease

    The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction or the first occurrence of transient ischaemic attack. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints.

    Time frame: From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])

  3. Number of Deaths From Any Cause

    Number of deaths from any cause. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints.

    Time frame: From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])

  4. Number of Patients With First Occurrence of a Composite Endpoint of Stroke, Haemorrhagic Events, or Cardiovascular Events

    The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction, or occurrence of cerebral haemorrhage, subarachnoid haemorrhage, transient ischaemic attack, angina pectris, myocardial infarction, heart failure, or haemorrhage requiring hospital admission. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints.

    Time frame: From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])

Other outcomes

  1. Number of Patients With First Occurrence of Haemorrhagic Event

    The endpoint in this measure is a composite endpoint of the first occurrence of cerebral haemorrhage, subarachnoid haemorrhage or haemorrhage requiring hospital admission. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints.

    Time frame: From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])

07

Results

Posted May 13, 2011

Participant flow

Patients with non-cardioembolic ischemic stroke have been recruited at 278 study sites in Japan between December, 2003, and October, 2006.

Participant flow — Overall Study
MilestoneCilostazolAspirin
Started13561360
Completed8811004
Not completed475356
Withdrew: Adverse event268166
Withdrew: Withdrawal by subject7356
Withdrew: Physician decision2322
Withdrew: Not classified111112

Outcome measures

PrimaryNumbers of Patients With First Occurence of Stroke

The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction, or occurrence of cerebral haemorrhage or subarachnoid haemorrhage. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints.

Time frame:
From start of treatment to end of follow-up period ( follow-up periods : 29 months [Standard Deviation 16, range 1-59 months])
Reported as:
Number · participants
Numbers of Patients With First Occurence of Stroke
participantsCilostazolAspirin
Numbers of Patients With First Occurence of Stroke82119
Statistical analysis
  • Cilostazol vs Aspirin · Log Rank · p = 0.0357 (The log-rank test was used to verify the superiority of CLZ to ASA only if non-inferiority was verified. The adjusted significance level for the superiority test of the endpoint was set at 0.0471 (two-tailed) according to the O'Brien-Fleming method.) · Hazard ratio, log: 0.743 · 95% CI 0.564 to 0.981
SecondaryNumber of Patients With First Recurrence of Cerebral Infarction
Time frame:
From start of treatment to end of follow-up period (mean follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])
Reported as:
Number · participants
Number of Patients With First Recurrence of Cerebral Infarction
participantsCilostazolAspirin
Number of Patients With First Recurrence of Cerebral Infarction7288
Statistical analysis
  • Cilostazol vs Aspirin · Log Rank · p = 0.4189 · Hazard ratio, log: 0.88 · 95% CI 0.645 to 1.200
SecondaryNumber of Patients With First Occurrence of Ischaemic Cerebrovascular Disease

The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction or the first occurrence of transient ischaemic attack. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints.

Time frame:
From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])
Reported as:
Number · participants
Number of Patients With First Occurrence of Ischaemic Cerebrovascular Disease
participantsCilostazolAspirin
Number of Patients With First Occurrence of Ischaemic Cerebrovascular Disease86103
Statistical analysis
  • Cilostazol vs Aspirin · Log Rank · p = 0.4582 · Hazard ratio (hr): 0.898 · 95% CI 0.675 to 1.194
SecondaryNumber of Deaths From Any Cause

Number of deaths from any cause. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints.

Time frame:
From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])
Reported as:
Number · participants
Number of Deaths From Any Cause
participantsCilostazolAspirin
Number of Deaths From Any Cause1313
Statistical analysis
  • Cilostazol vs Aspirin · Log Rank · p = 0.8600 · Hazard ratio (hr): 1.072 · 95% CI 0.497 to 2.313
SecondaryNumber of Patients With First Occurrence of a Composite Endpoint of Stroke, Haemorrhagic Events, or Cardiovascular Events

The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction, or occurrence of cerebral haemorrhage, subarachnoid haemorrhage, transient ischaemic attack, angina pectris, myocardial infarction, heart failure, or haemorrhage requiring hospital admission. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints.

Time frame:
From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])
Reported as:
Number · participants
Number of Patients With First Occurrence of a Composite Endpoint of Stroke, Haemorrhagic Events, or Cardiovascular Events
participantsCilostazolAspirin
Number of Patients With First Occurrence of a Composite Endpoint of Stroke, Haemorrhagic Events, or Cardiovascular Events138186
Statistical analysis
  • Cilostazol vs Aspirin · Log Rank · p = 0.0437 · Hazard ratio (hr): 0.799 · 95% CI 0.643 to 0.994
Other pre-specifiedNumber of Patients With First Occurrence of Haemorrhagic Event

The endpoint in this measure is a composite endpoint of the first occurrence of cerebral haemorrhage, subarachnoid haemorrhage or haemorrhage requiring hospital admission. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints.

Time frame:
From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])
Reported as:
Number · participants
Number of Patients With First Occurrence of Haemorrhagic Event
participantsCilostazolAspirin
Number of Patients With First Occurrence of Haemorrhagic Event2357
Statistical analysis
  • Cilostazol vs Aspirin · Log Rank · p = 0.0004 · Hazard ratio (hr): 0.458 · 95% CI 0.296 to 0.711

Adverse events

Collected over From start of treatment to end of follow-up period (mean follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months]). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cilostazol—372/1,337 (27.8%)1,267/1,337 (94.8%)
Aspirin—433/1,335 (32.4%)1,260/1,335 (94.4%)
Most frequent serious events
Showing 10 of 349
Most frequent serious events
EventCilostazolAspirin
Cerebral infarctionNervous system disorders62/133784/1335
Cerebral haemorrhageNervous system disorders4/133725/1335
CataractEye disorders22/133717/1335
Inguinal herniaGastrointestinal disorders11/13375/1335
Myocardial infarctionCardiac disorders10/13373/1335
Colonic polypGastrointestinal disorders10/13377/1335
Gastric ulcer haemorrhageGastrointestinal disorders1/13379/1335
PneumoniaInfections and infestations8/13379/1335
Transient ischaemic attackNervous system disorders8/13379/1335
Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)9/13378/1335
Most frequent other events
Showing 10 of 21
Most frequent other events
EventCilostazolAspirin
NasopharyngitisInfections and infestations546/1337590/1335
HeadacheNervous system disorders312/1337217/1335
HypertensionVascular disorders120/1337185/1335
Back painMusculoskeletal and connective tissue disorders160/1337165/1335
DiarrhoeaGastrointestinal disorders164/133785/1335
PalpitationsCardiac disorders156/133771/1335
ConstipationGastrointestinal disorders110/1337155/1335
ContusionInjury, poisoning and procedural complications128/1337121/1335
DizzinessNervous system disorders124/133792/1335
ArthralgiaMusculoskeletal and connective tissue disorders118/1337102/1335

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)CilostazolAspirinTotal
<=18 years000
Between 18 and 65 years6816851366
>=65 years6566501306
Age Continuous
Age Continuous(years)CilostazolAspirinTotal
Mean63.5 ± 9.263.4 ± 9.063.4 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)CilostazolAspirinTotal
Female378378756
Male9599571916
Region of Enrollment
Region of Enrollment(participants)CilostazolAspirinTotal
Japan133713352672
08

Study locations

1 site
  • Otsuka Pharmaceutical Co., Ltd.
    Tokyo, Japan
09

References and documents

Publications

  • Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kitagawa Y, Kusuoka H, Nishimaru K, Tsushima M, Koretsune Y, Sawada T, Hamada C; CSPS 2 group. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol. 2010 Oct;9(10):959-68. doi: 10.1016/S1474-4422(10)70198-8. Epub 2010 Sep 15. PubMed 20833591 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2003, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2005
First posted
Oct 6, 2005
Start
Dec 2003
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results first posted
May 13, 2011
Last update
Jun 10, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00234065
First posted
Oct 6, 2005
Start date
Dec 2003
Primary completion
Dec 2008
Completion
Dec 2008
Results posted
May 13, 2011
Last update
Jun 10, 2011

Study contacts

Masahiko Abe
study director · Division of New Product Evaluation and Development

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cilostazol

Start the discussion